This announcement is a separate document:
Heartseed：HS-001のLAPiS試験で安全性評価委員会が高用量群投与開始を推奨
Heartseed: In the HS-001 LAPiS trial, the Safety Evaluation Committee recommended the start of administration in the high-dose group.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.